

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Pharmacokinetics of anidulafungin in two critically ill patients with septic shock undergoing CVVH

This is the author's manuscript

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/141696> since 2021-04-29T12:35:36Z

Published version:

DOI:10.1179/1973947813Y.0000000089

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

Journal of Chemotherapy

Pharmacokinetics of Anidulafungin in Two Critically Ill Patients with Septic Shock Undergoing CVVH --Manuscript Draft--

Manuscript Number:	
Full Title:	Pharmacokinetics of Anidulafungin in Two Critically Ill Patients with Septic Shock Undergoing CVVH
Article Type:	Case Report
Keywords:	anidulafungin, pharmacokinetic, septic shock, critically ill patients, continuous veno-venous haemofiltration (CVVH), dialysis
Corresponding Author:	Francesco Giuseppe De Rosa, M.D. University of Turin ITALY
Corresponding Author Secondary Information:	
Corresponding Author's Institution:	University of Turin
Corresponding Author's Secondary Institution:	
First Author:	Francesco Giuseppe De Rosa, M.D.
First Author Secondary Information:	
Order of Authors:	Francesco Giuseppe De Rosa, M.D. silvia corcione, MD lorena baietto, BSc daniela Pasero, MD giovanni di perri, MD, PhD, DTM&H V. Marco ranieri, MD antonio d'avolio, BSc, MSc, Sc
Order of Authors Secondary Information:	
Manuscript Region of Origin:	ITALY
Abstract:	<p>Candidemia is associated with high mortality rate especially in critically ill (ICU) patients with septic shock and echinocandins such as anidulafungin are recommended as first line treatment. Available pharmacokinetic studies of anidulafungin in healthy volunteers and in patients with renal or hepatic impairment showed that no dose adjustment is needed even in patients receiving standard intermittent haemodialysis. However, few data are available with continuous veno-venous haemofiltration (CVVH). In this study the pharmacokinetic of anidulafungin was studied in two ICU patients with candidemia and septic shock undergoing CVVH. Both patients had satisfactory parameters of Cmax (9.04 mg/L and 5.68 mg/L, respectively), AUC (95.18 mg/L*h and 67.48 mg/L*h) and Cmin (2.61 mg/L and 1.43 mg/L). AUC/MIC ratio and Cmax/MIC values were: 11887 and 8435; 1130,25 and 710, for patient 1 and 2 respectively. Our data confirm that in patients with septic shock anidulafungin presents only mild pharmacokinetic changes compared to data reported during CVVH alone.</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

Introduction

Bloodstream infections caused by *Candida spp.* are associated with a mortality of 30-50%, especially in intensive care units (ICU), where the risk of invasive *Candida* infection is increased ¹. Echinocandins such as anidulafungin are fungicidal against *Candida spp.* and are recommended as first line agents by the IDSA and ESCMID guidelines¹⁻³. Anidulafungin has no known metabolism and undergoes spontaneous degradation at physiologic pH and temperature ⁴ and pharmacokinetic studies in healthy volunteers and in patients with renal or hepatic impairment demonstrated that no dose change is needed, also including patients undergoing standard intermittent haemodialysis⁵⁻⁶.

In patients with septic shock the pharmacokinetic of antimicrobials may dramatically change owing to tissue perfusion, change of protein binding, drug clearance and fluid overload which may increase the volume of distribution of many drugs ⁴. Continuous veno-venous haemofiltration (CVVH) is frequently used in ICU patients with renal failure and the pharmacokinetic of antifungals may be altered, according to various parameters both patient-related and extracorporeal circuit-related, such as the ultrafiltrate and dialysate rates, dialysate concentrations and the type of membranes.

There are very few data on pharmacokinetic of anidulafungin in ICU patients, either with septic shock or CVVH. The aim of this study was to describe the pharmacokinetics of anidulafungin in two ICU patients with septic shock during CVVH.

Material and methods

Anidulafungin plasmatic concentrations were studied in two ICU patients with septic shock, receiving CVVH and treated with standard dosage (100 mg/die preceded by loading dose of 200 mg, 1 hour of infusion) for candidemia. The area under the curve

1 (AUC), C_{\max} and C_{\min} were determined by collecting blood samples during CVVH at 0,
2 1, 5 and 8 hours after administration at steady state (after the day four from the beginning
3 of maintenance dose). Plasma samples were obtained and centrifuged at 3000 rpm for 10
4 minutes at 4°C; two samples were stored at -20°C until analysis. Anidulafungin was
5 determined in plasma by ultra performance liquid chromatography-photo diode array
6 detection (UPLC-PDA); a linear forced through zero calibration curve in the range of 15
7 mg/L to 0.117 mg/L, was used. Mean accuracy expressed as relative accuracy % was
8 94.4%. Precision, expressed as relative standard deviation %, was 6.39. Pharmacokinetic
9 data were obtained using Kinetica Software (Thermo Scientific, Waltham,
10 Massachusetts, USA). A non-compartmental steady state model was used.

11 The patients main clinical, microbiological and laboratory data are illustrated in Table 1.
12 Notably, patient 2 was receiving tacrolimus and cyclosporine because of heart transplant.

14 **Results**

15 Patients' clinical and microbiological characteristics are illustrated in Table 1. Mean
16 C_{\max} , C_{\min} , AUC, half life, clearance and volume of distribution were: 9.04 Vs. 5.68
17 mg/L; 2.61 Vs. 1.43 mg/L; 95.18 Vs. 67.48 mg/L*h; 31.99 Vs. 15.34 h; 2.6 Vs. 1.48 L/h;
18 48.48 Vs. 32.81 L for patient 1 and 2, respectively.

19 **Discussion**

20 The effect of septic shock on serum drug concentrations may be altered owing to
21 increased cardiac output, infusion of liquids, increased or decreased clearances with
22 secondary alterations of the volume of distribution; such changes may result in
23 insufficient dosages of antimicrobials, either for concentration- and time-dependent
24 molecules. Echinocandins are fungicidal against *Candida spp.* and are concentration-
25 dependent with best activity described by C_{\max}/MIC and AUC/MIC ^{4, 6}; anidulafungin

1 has the highest volume of distribution and, at least in theory, plasma concentration in
2 patients with septic shock may vary even if lipophylic molecules, such as anidulafungin,
3 better tolerate changes in body fluid volume^{7,8}. In ICU patients CVVH is commonly
4 used in septic patients with renal failure and it may further contribute to pharmacokinetic
5 alterations, depending on several variables, such as the ultrafiltrate and dialysate rates
6 and the type of membrane used.

7 Available data in non-ICU population pharmacokinetic analysis for anidulafungin show
8 that pharmacokinetic parameters associated with success include AUC at steady state >35
9 mg/L*h and minimum plasma concentration at steady state (C_{\min}) >1 mg/L⁶. The
10 strongest relationship with antifungal effect in animal models, considering the
11 pharmacokinetic/ pharmacodynamic parameters, was observed with AUC/MIC ratio of
12 250 and $C_{\max}/MIC > 4$ ^{5,9}.

13 Our patients did achieve $AUC/MIC > 250$ and $C_{\max}/MIC > 4$, perhaps due also to the very
14 low MIC of *C. albicans* tested. These results underscore that even in patients with septic
15 shock receiving CVVH anidulafungin has a very good pharmacokinetic profile.
16 According to the available literature, both patients (1 and 2, respectively) had satisfactory
17 parameters of C_{\max} , AUC and C_{\min} . AUC/MIC ratio and C_{\max}/MIC values considering the
18 MIC for *Candida albicans* (0.008 mg/L) were 11887 and 8435; 1130,25 and 710,
19 respectively, for patient 1 and 2. Notably, pharmacokinetic data for patient 2 confirm that
20 there are no significant interactions with tacrolimus or cyclosporine.

21 Of course we proceeded to simulate AUC/MIC ratio for different *Candida* MICs: the
22 ratios were 5948 and 4217 for patient 1 and 2, respectively, with MIC of 0.016 mg/L;
23 761 and 539 for MIC of 0.125 mg/L. The simulated values of C_{\max}/MIC considering MIC
24 values of 0.016 mg/L were 565.13 and 355, changing to 72.34 and 45.44 for patient 1 and
25 2, respectively with MIC of 0.125 mg/L. Despite early and appropriate empiric treatment

1 with anidulafungin before microbiological confirmation of candidemia and plenty
2 satisfaction of pharmacokinetic parameters, both patients were dead at 21 days after
3 diagnosis, with negative blood cultures at 48 hours after diagnosis.

4 To our knowledge there are few data on pharmacokinetic of anidulafungin in ICU
5 patients and no data are available in patients with septic shock undergoing CVVH. A case
6 report in the ICU setting by Burkhardt reported that anidulafungin does not necessitate
7 dose adjustment with septic shock undergoing extended daily dialysis ¹⁰. However,
8 pharmacokinetic parameters were only studied at the first day of treatment, when the
9 loading dose was administered: C_{max} , C_{min} and AUC values were 5.32 mg/L, 1.60 mg/L
10 and 55.2 mg *h/L, respectively. Leitner et al. described 10 patients receiving CVVH,
11 three of which with septic shock, with a CVVH ultrafiltration rate of 1500 ml/h, an
12 extended 3-h anidulafungin loading dose infusion and 1.5-h infusion maintenance dose
13 ¹¹. C_{max} values were evaluated at day 1, 2 and 3 whilst AUC was determined only during
14 the first day. This study reported a mean C_{max} of 5.9+ 2 mg/L at day 3 and a mean arterial
15 AUC of 109.9+ 49.82 mg*h/L at day 1. According to these data, the Authors concluded
16 that dose changes are not needed during CVVH.

17 In conclusion, anidulafungin treatment of ICU patients with septic shock and CVVH did
18 confirm that no dose changes are needed compared to patients treated with CVVH alone.

1 Table 1. Patients' clinical and microbiological characteristics.

	Patient 1	Patient 2
Sex	Female	Male
Age (year)	69	56
BMI	28	31
Comorbidities	Hypertension, diabetes, ischemic cardiopathy. Berger's nephritis. Peritoneal dialysis. Prosthetic aortic valve	Diabetes. Heart transplant complicated by surgical site infection and AKI. Immunesuppression with tacrolimus and cyclosporine
Days of ICU at diagnosis	20	24
Creatinine (mg/dl)	2.3	2.2
Albumin (mg/dl)	2.4	2.5
AKI/CRF	CRF	AKI
Therapy with Amine yes/no	Yes	Yes
Blood cultures	<i>C. albicans</i>	<i>C. albicans</i>
CVVH (ml/h)	2000	1800
MIC for Anidulafungin (mg/L)	<0.008	<0.008
Candida score¹²	4	4

2

3

4

References

5

1. Kett DH, Shorr AF, Reboli AC, ReismanAL, Biswas P, Schlamm HT

6

Anidulafungin compared with fluconazole in severely ill patients with candidemia and

7

other forms of invasive candidiasis: support for the 2009 IDSA treatment guidelines for

8

candidiasis. Crit Care. 2011;15

- 1 2. Ruhnke M, Paiva JA, Meersseman W, Pahl J, Grigoras I, Sganga G, et al.
2 Anidulafungin for the treatment of candidaemia/invasive candidiasis in selected critically
3 ill patients. *Clin Microbiol Infect.* 2012;18:680-687.
- 4 3. Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, et al.
5 Infectious Diseases Society of America. Clinical practice guidelines for the management
6 of candidiasis: 2009 update by the Infectious Diseases Society of America. *Clin Infect*
7 *Dis.* 2009;48:503-35.
- 8 4. Mazzei T, Novelli A. Pharmacological properties of antifungal drugs with a focus on
9 anidulafungin. *Drugs.* 2009;69:79-90.
- 10 5. Dowell JA, Knebel W, Ludden T, Stogniew M, Krause D, Henkel T. Population
11 pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. *J Clin*
12 *Pharmacol.* 2004;44:590-8.
- 13 6. Dowell JA, Stogniew M, Krause D, Damle B. Anidulafungin does not require dosage
14 adjustment in subjects with varying degrees of hepatic or renal impairment. *J Clin*
15 *Pharmacol.* 2007;47:461-70.
- 16 7. Mukherjee PK, Sheehan D, Puzniak L, Schlamm H, Ghannoum MA. Echinocandins: are
17 they all the same? *J Chemother.* 2011;23:319-25.
- 18 8. Krause DS, Reinhardt J, Vazquez JA, Reboli A, Goldstein BP, Wible M et
19 al. Anidulafungin Invasive Candidiasis Study Group. Phase 2, randomized, dose-ranging
20 study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and
21 candidemia. *Antimicrob Agents Chemother.* 2004;48:2021-4
- 22 9. Gumbo T. Impact of pharmacodynamics and pharmacokinetics on echinocandin dosing
23 strategies. *Curr Opin Infect Dis.* 2007;20:587-91.
- 24 10. Burkhardt O, Kaefer V, Burhenne H, Kielstein JT. Extended daily dialysis does not affect
25 the pharmacokinetics of anidulafungin. *Int J Antimicrob Agents.* 2009;34:282-3.

1
2
3
4
5
6
7
8
9
10
11
12

11. Leitner JM, Meyer B, Fuhrmann V, Saria K, Zuba C, Jäger W et al. Multiple-dose pharmacokinetics of anidulafungin during continuous venovenous haemofiltration. *J Antimicrob Chemother.* 2011;66:880-4.

12. León C, Ruiz-Santana S, Saavedra P, Almirante B, Nolla-Salas J, Alvarez-Lerma F, et al. EPCAN Study Group. A bedside scoring system ("Candida score") for early antifungal treatment in non-neutropenic critically ill patients with Candida colonization. *Crit Care Med.* 2006;34:730-7.

**Pharmacokinetics of Anidulafungin in Two Critically Ill Patients
with Septic Shock Undergoing CVVH**

Francesco G. De Rosa^{a#}, Silvia Corcione^a, Lorena Baietto^a, Daniela Pasero^b, Giovanni

Di Perri^a, V. Marco Ranieri^b and Antonio D'Avolio^a

Authors affiliation:

^a Dept. of Medical Sciences, University of Turin, Amedeo di Savoia Hospital, Italy

^b City of Science and Health - Molinette, Department of Anesthesia and Critical Care
Medicine, University of Turin- C.so Bramante 88, Turin, Italy

#Corresponding Author:

Prof. Francesco G. De Rosa, MD

Dept. of Medical Sciences

University of Turin

Amedeo di Savoia Hospital

Corso Svizzera 164, 10149, Turin, Italy

Tel +390114393979

Fax +390114393882

e-mail: francescogiuseppe.derosa@unito.it

Word count: 1088

Number of tables: 1

